Koja S, Itokazu T, Maeshiro N, Matsumura J, Maeda H, Yasuda S, Kochi A, Noda Y
Dept. of Otorhinolaryngology, University of the Ryukyus Faculty of Medicine.
Gan To Kagaku Ryoho. 1995 Jul;22(8):1047-50.
Forty-two patients with head and neck cancer were treated with tegafur suppository for 7 days preoperatively and clinical value of this treatment was assessed. In a group which indicated tumor tissue concentrations of 5-FU were more than 0.5 micrograms/g, local recurrence decreased in the period of postoperative observation for 42 months. A survival rate of this group was better than others. From these results, preoperative tegafur suppository treatment seemed to have a role in expectation of improvement of local control in head and neck cancer therapy.